BioSpace News Archive

US Drug Test Centers, one of the largest testing companies in the United States, announced they are now offering COVID-19 Antibody Testing with FDA Emergency Use Authorization at 1,800+ locations nationwide. No prescription is necessary.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that researchers across the globe are deploying its Simoa® technology to profile innate immune response in COVID-19 patients,

ivWatch, LLC, provider of continuous monitoring devices focused on improving patient safety and the effectiveness of intravenous (IV) therapy, today announced the issuance of two new patents in Japan and Australia, increasing the company’s patent portfolio to 31. ivWatch patented technology works in partnership with clinicians to reduce the harm

Viroclinics Biosciences B.V. (“Viroclinics”) today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company’s new Chief Executive Officer.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for the combination of NeoImmuneTech’s NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7)

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), will mark their 26th anniversary this week with the start of PPMD’s Virtual Annual Conference on Wednesday, July 22, 2020 at 6pm eastern.

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2020 second quarter financial results for Friday, July 31, 2020 before the market opens.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), today announced the closing of its previously announced underwritten public offering of an aggregate of 2,173,914 shares of its common stock at a public offering price of $10.00 per share and the exercise in full of the underwriters’ option to purchase an additional 326,086 shares of common stock.

Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2020 on Tuesday, August 4, 2020

A recently announced licensing agreement between drug maker Acadia Pharmaceuticals and Vanderbilt University represents a major milestone for the ADDF-Harrington Scholar Award Program, which provided funding and pharmaceutical expertise to support the research in the early phases.